Novo Nordisk Acquires Omeros’ Zaltenibart to Advance Rare Disease Portfolio
Bagsværd, Denmark & Seattle, USA – October 15, 2025 – In a move strengthening its foothold in immunology and...
DrugDevelopment
Advertisement
AbbVie Submits BLA for Pivekimab Sunirine to FDA for Rare Blood Cancer
North Chicago, IL – September 30, 2025 – AbbVie (NYSE: ABBV) announced the submission of a Biologics License Application...
Advertisement
